- Home
- UCL vs ANTX Comparison
UCL vs ANTX Comparison
Compare UCL & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- ANTX
- Stock Information
- Founded
- UCL 2014
- ANTX 2017
- Country
- UCL Hong Kong
- ANTX United States
- Employees
- UCL N/A
- ANTX N/A
- Industry
- UCL Telecommunications Equipment
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- ANTX Health Care
- Exchange
- UCL Nasdaq
- ANTX Nasdaq
- Market Cap
- UCL 48.7M
- ANTX 40.0M
- IPO Year
- UCL 2020
- ANTX 2022
- Fundamental
- Price
- UCL $2.13
- ANTX $1.27
- Analyst Decision
- UCL
- ANTX Hold
- Analyst Count
- UCL 0
- ANTX 5
- Target Price
- UCL N/A
- ANTX $3.50
- AVG Volume (30 Days)
- UCL 378.8K
- ANTX 387.1K
- Earning Date
- UCL 11-26-2024
- ANTX 11-13-2024
- Dividend Yield
- UCL N/A
- ANTX N/A
- EPS Growth
- UCL 169.91
- ANTX N/A
- EPS
- UCL 0.11
- ANTX N/A
- Revenue
- UCL $87,405,000.00
- ANTX N/A
- Revenue This Year
- UCL $11.23
- ANTX N/A
- Revenue Next Year
- UCL $27.52
- ANTX N/A
- P/E Ratio
- UCL $18.91
- ANTX N/A
- Revenue Growth
- UCL 4.73
- ANTX N/A
- 52 Week Low
- UCL $0.97
- ANTX $0.87
- 52 Week High
- UCL $3.30
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- UCL 62.21
- ANTX 43.86
- Support Level
- UCL $1.41
- ANTX $1.23
- Resistance Level
- UCL $3.30
- ANTX $1.59
- Average True Range (ATR)
- UCL 0.39
- ANTX 0.08
- MACD
- UCL 0.11
- ANTX -0.04
- Stochastic Oscillator
- UCL 45.33
- ANTX 8.11
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.